BioNTech Reinvents Itself: Founders Exit, $1 Billion Buyback, and Cancer Data Collide in Pivotal Week

BioNTech founders step away to launch new mRNA venture; strong oncology data at ASCO, 1,860 job cuts, and $1B buyback signal pivot from COVID to cancer.

BioNTech’s story has taken another turn. The company that became a household name during the pandemic is now pushing hard into oncology, and this week brings a convergence of events that could shape its trajectory for the rest of the decade. The founders, U?ur ?ahin and Özlem Türeci, are stepping away from day-to-day operations by year-end to launch a new mRNA research venture — a move that signals the beginning of a new chapter even as the old one is still winding down. BioNTech retains a minority stake in the spin-off and secures rights to certain next-generation technologies.

The leadership shift comes just as the company navigates a thicket of near-term catalysts. On the vaccine front, the FDA’s advisory panel VRBPAC voted on May 28 to recommend updating COVID-19 shots to target the XFG variant for the 2026/2027 autumn and winter campaign. BioNTech and partner Pfizer have signaled they are ready to manufacture the updated formula. That gives some revenue visibility for the infectious-disease segment, which generated roughly €118 million in the first quarter of 2026.

But the real focus is on cancer. BioNTech is presenting at the ASCO annual meeting in Chicago, where it is rolling out fresh data from its late-stage oncology pipeline. The spotlight falls on two programs. Pumitamig, developed with Bristol Myers Squibb, showed encouraging anti-tumor activity in a phase 2 interim analysis as a first-line therapy for lung cancer — the third global dataset to demonstrate consistent effects when combined with chemotherapy. Gotistobart, partnered with OncoC4, delivered durable tumor shrinkage and clinically relevant survival figures in platinum-resistant ovarian cancer.

The ASCO lineup also includes BNT324/DB-1311, an antibody-drug conjugate targeting prostate cancer, and BNT323 (trastuzumab pamirtecan) in recurrent endometrial cancer. In total, BioNTech now has more than 25 active phase 2 and phase 3 studies, with 13 serving as registration trials across lung, ovarian, prostate, and endometrial cancers. Management’s target is to boost that number to 15 by the end of 2026.

Financing such an ambitious build-out requires a hefty war chest. BioNTech closed the first quarter with cash, cash equivalents, and marketable securities totaling €16.8 billion. That cushion allows the company to absorb a net loss of roughly €532 million on revenue of just €118 million in Q1 — a predictable result of the transition away from COVID products. To streamline operations, BioNTech is cutting up to 1,860 jobs, or about 22% of its global workforce, and halting coronavirus vaccine production in Europe and Asia. The restructuring is expected to save up to €500 million annually by 2029, with the freed-up cash redirected into oncology R&D.

Shareholders are also getting a taste of the company’s confidence. A new buyback program of up to $1 billion has been authorized, running through May 2027 and funded from existing cash. Meanwhile, JPMorgan, which resumed coverage of 14 large biotech firms in mid-May, handed BioNTech a Neutral rating and a December 2026 price target of $100. That is above the current share price of around €81, but peers such as Vertex and Alnylam received more bullish assessments.

The stock itself has been treading water, trading almost exactly on its 50-day moving average — a sign of consolidation after falling roughly 21% from its 52-week high of €101.90. The seven additional late-stage data readouts scheduled for the second half of 2026 could provide the catalyst to break that stalemate. With the founders stepping back, a leaner cost structure taking shape, and a pipeline reaching critical mass, BioNTech is betting that its next act will be defined not by vaccines, but by oncology — and that the market will eventually reward the shift.